Phase 1 study of azacitidine in combination with evorpacept for higher-risk myelodysplastic syndrome (MDS)

被引：0
|
作者：
Garcia-Manero, Guillermo
Scott, Bart L.
Kishtagari, Ashwin
Sanikommu, Srinivasa R.
Al-Kali, Aref
Lee, Je-Hwan
Burgues, Juan M. Bergua
Diez-Campelo, Maria
Erba, Harry P.
Garcia-Hernandez, Carmen
Santillana, Guillermo Sanz
O'Connell, Casey
Jang, Jun-Ho
Shin, Dong-Yeop
Sayar, Hamid
Rao, Mayank
Schwartz, Richard S.
An, Grace
Jin, Feng
Forgie, Alison J.
Tsiatis, Athanasios C.
Altman, Jessica K.
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-CT060
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT060
引用
收藏
页数：2
相关论文
共 50 条
  • [41] A Phase 1b Study of Glasdegib in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia
    Sekeres, Mikkael A.
    Schuster, Michael W.
    Joris, Magalie
    Krauter, Jurgen
    Maertens, Johan A.
    Gyan, Emmanuel
    Kovacsovics, Tibor
    Verma, Amit
    Vyas, Paresh
    Wang, Eunice S.
    Ma, Weidong Wendy
    Zeremski, Mirjana
    Kudla, Arthur
    Chan, Geoffrey
    Zeidan, Amer M.
    BLOOD, 2019, 134
  • [42] Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study
    U Platzbecker
    F Braulke
    A Kündgen
    K Götze
    G Bug
    C Schönefeldt
    K Shirneshan
    C Röllig
    M Bornhäuser
    R Naumann
    J Neesen
    A Giagounidis
    W-K Hofmann
    G Ehninger
    U Germing
    D Haase
    M Wermke
    Leukemia, 2013, 27 : 1403 - 1407
  • [43] Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study
    Platzbecker, U.
    Braulke, F.
    Kuendgen, A.
    Goetze, K.
    Bug, G.
    Schoenefeldt, C.
    Shirneshan, K.
    Roellig, C.
    Bornhaeuser, M.
    Naumann, R.
    Neesen, J.
    Giagounidis, A.
    Hofmann, W-K
    Ehninger, G.
    Germing, U.
    Haase, D.
    Wermke, M.
    LEUKEMIA, 2013, 27 (06) : 1403 - 1407
  • [44] Phase 2 Study of Pevonedistat plus Azacitidine versus Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)/Chronic Myelomonocytic Leukemia (CMML) or Low-Blast Acute Myelogenous Leukemia (LB-AML) (NCT02610777): Subset Analysis in Higher-Risk MDS
    Watts, Justin
    Ades, Lionel
    Radinoff, Atanas
    Arnan Sangerman, Montserrat
    Cerrano, Marco
    Font Lopez, Patricia
    Zeidner, Joshua
    Campelo, Maria Diez
    Graux, Carlos
    Liesveld, Jane
    Selleslag, Dominik
    Tzvetkov, Nikolay
    Fram, Robert J.
    Zhao, Dan
    Bell, Jill
    Friedlander, Sharon
    Faller, Douglas V.
    Sekeres, Mikkael A.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S323 - S324
  • [45] PROLONGED SURVIVAL IN HIGHER-RISK MYELODYSPLASTIC SYNDROME (MDS) PATIENTS (PTS) WITH-7/DEL(7Q) TREATED WITH AZACITIDINE (AZA)
    Mufti, G. J.
    Garcia-Manero, G.
    Hovarth, N.
    Lim, Z.
    Quesnel, B.
    Leone, G.
    Bennett, J.
    Sanz, G.
    McKenzie, D.
    Backstrom, J.
    Beach, C. L.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 369 - 370
  • [46] Phase I Combination Trial of Lenalidomide and Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes (vol 28, pg 2253, 2010)
    Ganetzky, Rebecca
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18) : 3098 - 3098
  • [47] Magrolimab plus azacitidine versus azacitidine plus placebo in untreated higher risk (HR) myelodysplastic syndrome (MDS): The phase 3, randomized, ENHANCE study.
    Garcia-Manero, Guillermo
    Daver, Naval Guastad
    Xu, Jin
    Chao, Mark
    Chung, Trisha
    Tan, Anderson
    Wang, Vivian
    Wei, Andrew
    Vyas, Paresh
    Sallman, David Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [48] TREATMENT OF HIGHER-RISK MYELODYSPLASTIC SYNDROME (MDS) WITH AZACITIDINE: A 4-YEAR POPULATION-BASED ANALYSIS FROM BRITISH COLUMBIA, CANADA
    Ankenman, M.
    Hogge, D.
    Narayanan, S.
    Power, M.
    Abou Mourad, Y.
    Barnett, M.
    Nantel, S.
    Sutherland, H.
    Forrest, D.
    Broady, R.
    Toze, C.
    Gerrie, A.
    Song, K.
    Nevill, T.
    HAEMATOLOGICA, 2015, 100 : 240 - 241
  • [49] A PHASE4, OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS (PK) OF SUBCUTANEOUS (SC) AZACITIDINE IN TAIWANESE SUBJECTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS)
    Laille, E.
    Chou, W.
    Yeh, S.
    Dong, Q.
    Songer, S.
    Beach, C.
    HAEMATOLOGICA, 2013, 98 : 577 - 578
  • [50] Phase II Study of Oral Rigosertib Combined with Azacitidine (AZA) As First Line Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS)
    Navada, Shyamala C.
    Garcia-Manero, Guillermo
    Atallah, Ehab L.
    Rajeh, M. Nabeel
    Shammo, Jamile M.
    Griffiths, Elizabeth A.
    Khaled, Samer K.
    Dakhil, Shaker R.
    Young, David E.
    Odchimar-Reissig, Rosalie
    Adesanya, Afoluso Ronnee
    Zbyszewski, Patrick S.
    Woodman, Richard C.
    Fenaux, Pierre
    Silverman, Lewis R.
    BLOOD, 2019, 134
12345